Genmab A/S ADR (GMAB) Stock Price, Quote & News

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 20 27 28

Website: www.genmab.com

Address:

Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

Quantumup Aug. 19 at 11:20 AM

BMO Capital🏁 $BCAX and said -- We are initiating coverage of Bicara Therapeutics with an Outperform rating and $35 target price. MRUS - $GMAB $LLY MRK BMY AZN INCY BMO Capital added—Bicara's bispecific, ficerafusp alfa, is a differentiated HNSCC asset with the potential to deliver broader, deeper, and more durable responses. The pivotal FORTIFI-HN01 interim analysis in mid-2027 is the key value inflection point, wherein a clear translation of strong Ph 1b activity indicates a strong market positioning, paving a path to accelerated approval in 2028 for a ~$2 billion peak sales opportunity. Other solid tumor opportunities, including mCRC, can provide additional upside potential.

0 · Reply

JimmyOcarri Aug. 17 at 7:59 PM

$PSX $WCC $INCY $GMAB $GH easy

0 · Reply

Quantumup Aug. 12 at 12:50 PM

BTIG y'day⬆️ $BCAX's PT to $39 and reiterated Buy after BCAX reported 2Q26 earnings. MRUS - $GMAB $MRK LLY AZN INCY Here's what BTIG said: https://x.com/Quantumup1/status/2087521829992681535?s=20

0 · Reply

EarningsInsider Aug. 6 at 5:32 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-genmab-as-stock/ $GMAB Genmab A/S Earnings Transcript

0 · Reply

anvesti Aug. 5 at 7:51 PM

Anvesti closed a long position $GMAB 🟢 +0.62% $29.12 → $29.30 Model: ml_model_v3 · Score: 79.4 Reason: Earnings Protection · 21 days

0 · Reply

BeverlyWilliams802 Aug. 5 at 6:53 AM

$RBC $GMAB $PFGC $IEX $RGLD RBC remains one of Canada's strongest banks, Genmab advances antibody therapies, Performance Food Group benefits from restaurant demand, IDEX develops industrial technologies, and Royal Gold benefits from royalty exposure.

0 · Reply

SenefAS Jul. 28 at 8:10 PM

When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ

0 · Reply

anachartanalyst Jul. 22 at 7:02 PM

$GMAB https://anachart.com/wp-content/uploads/2026/07/1784746938_soc-img.jpg

0 · Reply

elmono Jul. 22 at 2:44 PM

$GMAB $INCY $KPTI $XBI I am going to make so much money of KPTI that it will dwarf anything so far….8 B potential buy out if EC isxa success and MF OS number continues to hold up…just saying

1 · Reply

JuggernautRaider Jul. 22 at 5:26 AM

$KPTI $XBI karyopharm is screwed. Partially because they kept Tricky Dick Paulson as president for 5 years and keep paying him a fortune as the stock drops to NOTHING. Also, endometrial? Keytruda dominates that market now. Also why did they not pursue a phase 2 for glioblastoma? How did $INCY or $GMAB not buy KPTI for pennies on the dollar and huge tax writeoffs? WHY RICHARD? Why? 😤

2 · Reply

Capital Increase in Genmab as a Result of Employee Warrant Exercise

2026-08-07T16:43:50.000Z - 11 days ago

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

2026-08-07T13:42:12.000Z - 11 days ago

Genmab price target raised to $35 from $33 at Morgan Stanley

2026-08-07T11:41:22.000Z - 12 days ago

Genmab price target raised to $42 from $40 at Guggenheim

2026-08-07T00:52:17.000Z - 12 days ago

Genmab (GMAB) Q2 2026 Earnings Call Transcript

2026-08-06T21:48:00.000Z - 12 days ago

Genmab A/S Q2 Profit Declines

Thu, 06 Aug 2026 14:04:58 -0400 - 12 days ago

Genmab A/S Q2 Earnings Call Highlights

Aug 6, 2026, 12:00 PM EDT - 12 days ago

Genmab Earnings Call Transcript: Q2 2026

Aug 6, 2026, 12:00 PM EDT - 12 days ago

Genmab Quarterly report: Q2 2026

Aug 6, 2026, 12:00 PM EDT - 12 days ago

Genmab Slides: Q2 2026

2026-08-06T15:10:36.000Z - 12 days ago

Genmab reports Q2 revenue $1.155B vs. $925M last year

2026-08-06T15:10:29.000Z - 12 days ago

Genmab raises FY26 revenue view to $4.325B-$4.525B from $4.065B-$4.395B

2026-08-05T13:18:54.000Z - 13 days ago

Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside

2026-07-24T13:56:04.000Z - 25 days ago

AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint

2026-07-24T06:22:19.000Z - 26 days ago

Genmab & AbbVie's Epcoritamab Fails To Meet Primary Goal In Phase 3 EPCORE DLBCL-1 Trial

$Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

2026-07-23T20:06:00.000Z - 26 days ago

Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-07-23T20:05:43.000Z - 26 days ago

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

ABBV

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jul 23, 2026, 4:00 PM EDT - 26 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

ABBV GMAB

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

2026-07-23T20:00:00.000Z - 26 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-07-22T10:25:54.000Z - 4 weeks ago

Genmab upgraded to Buy from Hold at TD Cowen

2026-07-15T11:06:00.000Z - 5 weeks ago

Genmab Reports Q2 Worldwide Net Trade Sales Of DARZALEX

2026-07-15T10:30:32.000Z - 5 weeks ago

Genmab reports Q2 net sales of Darzalex $4.207B

JNJ

Jul 15, 2026, 6:22 AM EDT - 5 weeks ago

Market Cap	20.48B
Revenue (ttm)	3.72B
Net Income (ttm)	963.00M
EPS (ttm)	N/A
PE Ratio	22.98
Forward PE	27.38
Profit Margin	25.89%
Debt to Equity Ratio	0.86

Volume	2,706,900
Avg Vol	2,085,748
Day's Range	N/A - N/A
Shares Out	623.53M
Stochastic %K	97%
Beta	0.83
Analysts	Strong Sell
Price Target	$38.60